Computational Analysis of HLA-presentation of Non-synonymous Recipient Mismatches Indicates Effect on the Risk of Chronic Graft-vs.-Host Disease After Allogeneic HSCT.
Genotype
Graft vs Host Disease
/ immunology
Graft vs Leukemia Effect
/ immunology
Hematopoietic Stem Cell Transplantation
/ methods
Histocompatibility
/ immunology
Histocompatibility Testing
/ methods
Humans
Minor Histocompatibility Antigens
/ immunology
Siblings
Tissue Donors
Transplantation, Homologous
/ methods
HLA
HSCT
genomics
graft-vs.-host
minor histocompatibility antigen
whole-exome sequencing
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2019
2019
Historique:
received:
20
03
2019
accepted:
01
07
2019
entrez:
6
8
2019
pubmed:
6
8
2019
medline:
21
10
2020
Statut:
epublish
Résumé
Genetic mismatches in protein coding genes between allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipient and donor can elicit an alloimmunity response via peptides presented by the recipient HLA receptors as minor histocompatibility antigens (mHAs). While the impact of individual mHAs on allo-HSCT outcome such as graft-vs.-host and graft-vs.-leukemia effects has been demonstrated, it is likely that established mHAs constitute only a small fraction of all immunogenic non-synonymous variants. In the present study, we have analyzed the genetic mismatching in 157 exome-sequenced sibling allo-HSCT pairs to evaluate the significance of polymorphic HLA class I associated peptides on clinical outcome. We applied computational mismatch estimation approaches based on experimentally verified HLA ligands available in public repositories, published mHAs, and predicted HLA-peptide affinites, and analyzed their associations with chronic graft-vs.-host disease (cGvHD) grades. We found that higher estimated recipient mismatching consistently increased the risk of severe cGvHD, suggesting that HLA-presented mismatching influences the likelihood of long-term complications in the patient. Furthermore, computational approaches focusing on estimation of HLA-presentation instead of all non-synonymous mismatches indiscriminately may be beneficial for analysis sensitivity and could help identify novel mHAs.
Identifiants
pubmed: 31379830
doi: 10.3389/fimmu.2019.01625
pmc: PMC6646417
doi:
Substances chimiques
Minor Histocompatibility Antigens
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1625Références
Nat Med. 2001 Jul;7(7):789-94
pubmed: 11433342
Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2742-7
pubmed: 12601144
Protein Sci. 2003 May;12(5):1007-17
pubmed: 12717023
J Immunol. 1992 Sep 1;149(5):1788-94
pubmed: 1380540
Immunogenetics. 2005 Jun;57(5):304-14
pubmed: 15868141
BMC Bioinformatics. 2005 May 31;6:132
pubmed: 15927070
J Immunol. 2007 Mar 15;178(6):3558-65
pubmed: 17339452
Nat Rev Immunol. 2007 May;7(5):340-52
pubmed: 17438575
Immunome Res. 2008 Jan 25;4:2
pubmed: 18221540
Lancet. 2009 May 2;373(9674):1550-61
pubmed: 19282026
Nat Genet. 2009 Dec;41(12):1341-4
pubmed: 19935662
Biol Blood Marrow Transplant. 2010 Oct;16(10):1370-81
pubmed: 20353833
Immunogenetics. 2010 Jun;62(6):357-68
pubmed: 20379710
Immunology. 2010 Jul;130(3):319-28
pubmed: 20408898
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
Cancer Res. 2010 Nov 15;70(22):9073-83
pubmed: 21062987
Nat Rev Genet. 2011 Jan;12(1):32-42
pubmed: 21102527
Biol Blood Marrow Transplant. 2011 Jan;17(1 Suppl):S33-8
pubmed: 21195308
PLoS One. 2011;6(6):e21699
pubmed: 21738768
Immunogenetics. 2012 Mar;64(3):177-86
pubmed: 22009319
Biol Blood Marrow Transplant. 2013 Feb;19(2):274-82
pubmed: 23022467
Int J Immunogenet. 2013 Dec;40(6):495-501
pubmed: 23480177
Biol Blood Marrow Transplant. 2013 Aug;19(8):1244-53
pubmed: 23756210
Blood. 2013 Oct 31;122(18):3220-9
pubmed: 24046013
PLoS Comput Biol. 2013 Oct;9(10):e1003266
pubmed: 24204222
Nucleic Acids Res. 2014 Jan;42(Database issue):D749-55
pubmed: 24316576
Nat Commun. 2014 Apr 09;5:3600
pubmed: 24714562
Br J Haematol. 2014 Aug;166(4):566-70
pubmed: 24749631
Nucleic Acids Res. 2015 Jan;43(Database issue):D405-12
pubmed: 25300482
Front Immunol. 2014 Nov 06;5:529
pubmed: 25414699
Curr Protoc Bioinformatics. 2013;43:11.10.1-33
pubmed: 25431634
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
Blood. 2015 May 14;125(20):3193-201
pubmed: 25766725
Science. 2015 Apr 3;348(6230):69-74
pubmed: 25838375
Genet Epidemiol. 2015 Dec;39(8):619-23
pubmed: 26394715
Leukemia. 2016 Jun;30(6):1344-54
pubmed: 26857467
Front Immunol. 2016 Mar 15;7:100
pubmed: 27014279
BMC Med Genomics. 2016 Sep 13;9(1):59
pubmed: 27624058
Blood. 2017 Feb 9;129(6):791-798
pubmed: 27872059
Nucleic Acids Res. 2018 Jan 4;46(D1):D754-D761
pubmed: 29155950
PLoS One. 2017 Dec 1;12(12):e0187771
pubmed: 29194460
Sci Rep. 2018 Mar 29;8(1):5396
pubmed: 29599509
Leukemia. 2019 Jan;33(1):240-248
pubmed: 30089915
Blood Adv. 2018 Oct 9;2(19):2419-2429
pubmed: 30262602
Genome Biol. 2018 Nov 14;19(1):179
pubmed: 30424772